scholarly journals A retrospective analysis of venous thromboembolism trends in chemotherapy‐induced anemia: Red blood cell transfusion versus erythrocyte stimulating agent administration

eJHaem ◽  
2020 ◽  
Vol 1 (1) ◽  
pp. 35-43
Author(s):  
Emily J. Bryer ◽  
Michael J. Kallan ◽  
Ting‐Shan Chiu ◽  
Katharina M. Scheuba ◽  
David H. Henry
Keyword(s):  
Venous Thromboembolism ◽  
Blood Cell ◽  
Retrospective Analysis ◽  
Red Blood Cell ◽  
Red Blood Cell Transfusion

Association of Perioperative Red Blood Cell Transfusion With Symptomatic Venous Thromboembolism Following Total Hip and Knee Arthroplasty

2021 ◽  
Vol 36 (1) ◽  
pp. 325-330
Author(s):  
Aaron Jackson ◽  
Karan Goswami ◽  
Michael Yayac ◽  
Timothy L. Tan ◽  
Samuel Clarkson ◽  
...  
Keyword(s):  
Venous Thromboembolism ◽  
Blood Cell ◽  
Knee Arthroplasty ◽  
Red Blood Cell ◽  
Red Blood Cell Transfusion ◽  
Total Hip ◽  
Hip And Knee Arthroplasty

A retrospective analysis of venous thromboembolism trends in chemotherapy-induced anemia: Red blood cell transfusion versus erythrocyte stimulating agent (ESA) administration.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e14685-e14685
Author(s):  
Emily Jane Bryer ◽  
David H. Henry
Keyword(s):  
Venous Thromboembolism ◽  
Blood Cell ◽  
Red Blood Cell ◽  
Absolute Risk ◽  
Subsequent Development ◽  
Intravenous Iron ◽  
Red Blood Cell Transfusion ◽  
Chemotherapy Patients ◽  
Poor Outcomes ◽  
Rbc Transfusion

e14685 Background: Anemia is a common and unfortunate consequence of chemotherapy; patients receiving a variety of chemotherapy regimens often develop chemotherapy–induced anemia (CIA), which contributes to poor outcomes including increased mortality. Prompt and effective treatment of CIA is essential to prevent fewer chemotherapy dose delays and reductions. Optimal therapy of CIA is controversial and involves the solitary and combined use of intravenous iron, red blood cell (RBC) transfusions, and erythropoietin stimulating agents (ESAs). Despite the baseline coagulopathies present in patients with malignancy, administration of both RBC transfusions and ESAs is associated with venous thromboembolism (VTE). It remains unknown whether the risk of VTE in patients with CIA is greater among patients who receive RBC transfusions or ESAs. Methods: A retrospective single-institution study analyzed 7360 patients with varying malignancies who developed CIA and received ESAs and RBC transfusion from 1998-2017. These patients were evaluated for subsequent development of VTE and categorized by prior receipt of RBC transfusion or ESA. Results: Among the 7360 patients with CIA, 5503 received either RBC transfusion or ESA and 1857 received both. Among all patients, 3466/7360 (47.1%) developed a VTE. The absolute risk of developing a VTE with receipt of a RBC transfusion was 0.38 compared to 0.19 with ESA. Patients with CIA who received RBC had twice the risk of developing a VTE compared with those who received ESA (p < 0.0001). Conclusions: While both RBC transfusion and ESA administration are independently associated with VTE, our data suggests a greater risk of VTE development with RBC transfusion as compared with ESA administration.[Table: see text]

scholarly journals A 19-Year Retrospective Analysis of Venous Thromboembolism Trends in Chemotherapy-Induced Anemia: Red Blood Cell Transfusion Versus Erythrocyte Stimulating Agent Administration

Blood ◽  
2019 ◽  
Vol 134 (Supplement_1) ◽  
pp. 4944-4944
Author(s):  
Emily Bryer ◽  
Michael Kallan ◽  
Ting-Shaun Chiu ◽  
Katerina Scheuba ◽  
David H. Henry
Keyword(s):  
Venous Thromboembolism ◽  
Blood Cell ◽  
Red Blood Cell ◽  
Cox Regression ◽  
Conflicts Of Interest ◽  
Intravenous Iron ◽  
Red Blood Cell Transfusion ◽  
Chemotherapy Patients ◽  
Poor Outcomes ◽  
Rbc Transfusion

Introduction: Anemia is a common and unfortunate consequence of chemotherapy; patients receiving a variety of chemotherapy regimens often develop chemotherapy-induced anemia (CIA), which contributes to poor outcomes including increased mortality. Prompt and effective treatment of CIA is essential to prevent fewer chemotherapy dose delays and reductions. Optimal therapy of CIA is controversial and involves the solitary and combined use of intravenous iron, red blood cell (RBC) transfusions, and erythropoietin stimulating agents (ESAs). Despite the baseline coagulopathies present in patients with malignancy, administration of both RBC transfusions and ESAs is independently associated with venous thromboembolism (VTE). It remains unknown whether the risk of VTE in patients with CIA is greater among patients who receive RBC transfusions or ESAs. Methods: A retrospective study analyzed 13,334 patients in the University of Pennsylvania Health System with malignancies of various type, stage, and histopathology who developed CIA between 1998-2017. Using multivariate Cox regression, we determined adjusted hazard ratios (and corresponding 95% confidence intervals) of VTE development after adjusting for RBC and ESA intervention (all during the 90 days following CIA diagnosis). Results: (Table 1) Among the 13,334 patients with CIA, 10,948 patients did not receive any therapy during the 90-day period for their anemia (neither RBC nor ESA), 1,892 received RBC transfusion, 368 received ESA, and 126 patients received both. Among all patients, 2,620 (19.7%) developed a VTE within the 90-day period. VTE risk following RBC transfusion (HR=2.18, 95% CI 1.98-2.39, p<0.001) was approximately four-fold the VTE risk following ESA administration (HR=0.55, 95% CI 0.42-0.72, p<0.001). Conclusion: While both RBC transfusion and ESA administration are associated with VTE, our data suggests a greater risk of VTE development with RBC transfusion as compared with ESA administration. Disclosures No relevant conflicts of interest to declare.

Association between delivery methods for red blood cell transfusion and the risk of venous thromboembolism: a longitudinal study

2016 ◽  
Vol 3 (12) ◽  
pp. e563-e571 ◽  
Author(s):  
Mary A M Rogers ◽  
Neil Blumberg ◽  
Steven J Bernstein ◽  
Scott A Flanders ◽  
Vineet Chopra
Keyword(s):  
Longitudinal Study ◽  
Venous Thromboembolism ◽  
Blood Cell ◽  
Red Blood Cell ◽  
Red Blood Cell Transfusion ◽  
Delivery Methods
Sign in / Sign up

Export Citation Format

Share Document